The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH)
on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Background Non-T-cell depleted haploidentical hematopoietic stem cell transplantation
(HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with …

Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least
comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in …

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant
cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We …

In the era of targeted therapies, haematopoietic stem-cell transplantation (HSCT), both
allogeneic and autologous, remains a curative approach for patients with chemosensitive …

Haploidentical donor stem cell transplantation (haplo-SCT) has made great advances in
recent decades. The granulocyte colony-stimulating factor (G-CSF)-and antithymocyte …

Haploidentical stem cell transplantation (haplo-SCT), an alternative donor source, offers a
curative therapy for patients with acute myeloid leukemia (AML) who are transplant …

Advancements in the field of cellular immunotherapy have accelerated in recent years and
have changed the treatment landscape for a variety of hematologic malignancies. Cellular …

The outcome of allogeneic hematopoietic cell transplantation (allo-HCT) largely depends on
the development and management of graft-versus-host disease (GvHD), infections, and the …